Aardvark Therapeutics (AARD) Investors: Securities Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline

Aardvark Therapeutics faces a pending securities class action alleging it overstated ARD-101’s safety and clinical prospects; the allegations have not been adjudicated. The company voluntarily paused its Phase 3 HERO trial on February 27, 2026, after reversible cardiac observations at above-target doses, and the FDA placed the ARD-101 IND on full clinical hold on May 14, halting studies including HERO and the open-label extension. Aardvark shares fell more than 56% after the pause announcement and another 32.1% after the FDA hold; the lead-plaintiff motion deadline is October 13, 2026.

Analysis

The lawsuit notice is a secondary catalyst, not a new read-through on ARD-101’s safety: the key valuation variable remains whether the FDA hold can be resolved and the program restarted on an acceptable protocol. A lead-plaintiff deadline is procedural, not evidence that allegations have been proven; near-term legal headlines may add volatility but should not be confused with a change in clinical probability. The asymmetric risk is that a hold-resolution path may require additional studies, time, or dose changes that erode the program’s value even if the cardiac observations are reversible. Conversely, a credible FDA path could sharply reprice a small clinical-stage name, making an unhedged short vulnerable to squeezes. Over 1–3 months, monitor FDA/company updates and any protocol or trial redesign; over 6–18 months, the thesis depends on resumed enrollment and interpretable clinical data. The company’s cash runway, asset concentration, financing needs, FDA correspondence, and available options liquidity are not established here and must be verified before sizing. The downside thesis is falsified by a clearly defined FDA path to restart without material new safety requirements; it strengthens if the hold persists, the dose must be reduced enough to compromise efficacy, or financing is needed before meaningful data.

Key Decisions for Investors

• Avoid treating the class-action announcement itself as a fresh fundamental short signal. The allegations remain unproven, and the lead-plaintiff process is not a merits ruling.
• For existing AARD exposure, keep position size tied to verified cash runway and the probability of an FDA restart; do not average down until the company or FDA provides a concrete hold-resolution path.
• A bearish options expression is only a watch item: consider a defined-risk put spread if options are sufficiently liquid and implied volatility does not already price an extreme outcome. Avoid an uncapped short without checking borrow, float, and squeeze risk.
• Track the next company/FDA update for specific restart conditions, dose changes, and required safety work, and verify cash, pipeline breadth, and financing runway. A long becomes more defensible only if the regulatory path is explicit and the required dose appears clinically viable.